ABL1 (Y253F)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.Y253F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.7% | 0.3% | 78.23 |
| 2 | Bosutinib | 99.5% | 0.5% | 87.22 |
| 3 | Dasatinib | 98.9% | 1.1% | 87.97 |
| 4 | Nintedanib | 98.4% | 1.6% | 90.23 |
| 5 | Vandetanib | 95.5% | 4.5% | 95.74 |
| 6 | Pacritinib | 94.5% | 5.5% | 88.64 |
| 7 | Nilotinib | 93.9% | 6.1% | 96.49 |
| 8 | Axitinib | 92.0% | 8.0% | 93.23 |
| 9 | Crizotinib | 91.7% | 8.3% | 91.39 |
| 10 | Repotrectinib | 91.6% | 8.4% | 84.21 |
| 11 | Tivozanib | 90.8% | 9.2% | 92.42 |
| 12 | Erdafitinib | 90.8% | 9.2% | 95.71 |
| 13 | Canertinib | 88.8% | 11.3% | 96.49 |
| 14 | Brigatinib | 86.8% | 13.2% | 82.96 |
| 15 | Lenvatinib | 84.1% | 15.9% | 97.74 |
| 16 | Dacomitinib | 71.7% | 28.3% | 97.99 |
| 17 | Sunitinib | 65.7% | 34.3% | 91.73 |
| 18 | Entrectinib | 64.3% | 35.7% | 93.69 |
| 19 | Fedratinib | 61.7% | 38.3% | 96.21 |
| 20 | Erlotinib | 61.1% | 38.9% | 99.75 |
| 21 | Alectinib | 60.7% | 39.3% | 95.49 |
| 22 | Afatinib | 51.6% | 48.4% | 98.50 |
| 23 | Pazopanib | 51.1% | 48.9% | 97.49 |
| 24 | Gilteritinib | 45.6% | 54.4% | 88.97 |
| 25 | Selpercatinib | 44.1% | 55.9% | 96.72 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.7% | 100.0% | -0.3% |
| Bosutinib | 99.5% | 99.7% | -0.2% |
| Dasatinib | 98.9% | 98.6% | +0.3% |
| Nintedanib | 98.4% | 99.9% | -1.5% |
| Vandetanib | 95.5% | 95.7% | -0.2% |
| Pacritinib | 94.5% | 92.0% | +2.5% |
| Nilotinib | 93.9% | 98.0% | -4.1% |
| Axitinib | 92.0% | 99.4% | -7.4% |
| Crizotinib | 91.7% | 97.0% | -5.3% |
| Repotrectinib | 91.6% | 93.6% | -2.0% |
| Tivozanib | 90.8% | 95.8% | -5.0% |
| Erdafitinib | 90.8% | 90.9% | -0.1% |
| Canertinib | 88.8% | 91.6% | -2.8% |
| Brigatinib | 86.8% | 82.8% | +3.9% |
| Lenvatinib | 84.1% | 76.3% | +7.7% |
| Dacomitinib | 71.7% | 80.8% | -9.1% |
| Sunitinib | 65.7% | — | — |
| Entrectinib | 64.3% | — | — |
| Fedratinib | 61.7% | 82.7% | -21.0% |
| Erlotinib | 61.1% | — | — |
| Alectinib | 60.7% | — | — |
| Afatinib | 51.6% | — | — |
| Pazopanib | 51.1% | 77.5% | -26.4% |
| Gilteritinib | 45.6% | — | — |
| Selpercatinib | 44.1% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.2ms